A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept
The purpose of this study is to understand the treatment patterns and clinical outcomes of myelodysplastic syndromes patients treated with luspatercept or erythropoiesis-stimulating agents
Myelodysplastic Syndromes (MDS)
DRUG: Luspatercept|DRUG: Erythropoiesis-stimulating agent (ESA)
Participant baseline demographics, Baseline|Luspatercept dose at treatment initiation, Cohort 1 and 3 only, Baseline|Luspatercept dose at treatment discontinuation, Cohort 1 and 3 only, Up to 50 months|Luspatercept dose change or escalation or reduction, Cohort 1 and 3 only, Up to 50 months|Time from luspatercept initiation to the first occurrence of dose escalation, Cohort 1 and 3 only, Up to 50 months|Proportion of participants that discontinued treatment, Up to 50 months|Time from treatment initiation to treatment discontinuation, Up to 50 months|Time from luspatercept/erythropoiesis stimulating agents treatment initiation to initiation of a new treatment for myelodysplastic syndromes, Up to 50 months
The purpose of this study is to understand the treatment patterns and clinical outcomes of myelodysplastic syndromes patients treated with luspatercept or erythropoiesis-stimulating agents